From the management of microtubules to the production of pathological species: liquid-liquid phase separation may tune the behavior of the protein tau in health and neurodegenerative disease. In this issue of The EMBO Journal, Hochmair et al (2022) demystify important aspects of tau condensate compilation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156963 | PMC |
| http://dx.doi.org/10.15252/embj.2022111425 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of exposure time on optical-phase measurements in turbulence.
J Opt Soc Am A Opt Image Sci Vis
August 2024
In this paper, we explore the impact of exposure time on optical-phase measurements collected on light that has propagated through atmospheric-optical turbulence. We model the exposure time by phase averaging over a convective distance, and we quantify the associated impact of imposing an exposure time using the piston- and tilt-removed phase variance. We accomplish this analysis through the development of an analytic solution and wave-optics simulations.
View Article and Find Full Text PDFNew Research on Biomarkers in Alzheimer's Continuum.
Rev Recent Clin Trials
January 2025
Researcher of CNR-IBFM, Secondary Site, Azienda Ospedaliero-Universitaria "Renato Dulbecco" Catanzaro, Italy.
Alzheimer's disease (AD) is a multifactorial pathology, responsible for neurodegenerative disorders which in more than 60% of patients evolve into dementia. Comprehension of the molecular mechanisms underlying the pathology and the development of reliable diagnostic methods have made new and more effective therapies possible. In recent years, in addition to the classic anticholinesterases (AChEs), which can control the clinical symptoms of the disease, compounds able to reduce deposits of amyloid-β (Aβ) and/or tau (τ) protein aggregates, which are disease-modifying therapeutics (DMTs), have been studied.
View Article and Find Full Text PDFIntranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial.
Lancet Neurol
February 2025
Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada; Department of Cognitive Neurology, St Joseph's Health Care London, London, ON, Canada. Electronic address:
Background: No treatments exist for apathy in people with frontotemporal dementia. Previously, in a randomised double-blind, placebo-controlled, dose-finding study, intranasal oxytocin administration in people with frontotemporal dementia improved apathy ratings on the Neuropsychiatric Inventory over 1 week and, in a randomised, double-blind, placebo-controlled, crossover study, a single dose of 72 IU oxytocin increased blood-oxygen-level-dependent signal in limbic brain regions. We aimed to determine whether longer treatment with oxytocin improves apathy in people with frontotemporal dementia.
View Article and Find Full Text PDFFrom solubility to efficiency: Per- and polyfluoroalkyl substances (PFAS) regeneration from anion exchange resins.
Sci Total Environ
January 2025
Department of Civil and Environmental Engineering, Temple University, Philadelphia, PA 19122, USA. Electronic address:
This study investigated the regenerability of anion exchange resins for per- and polyfluoroalkyl substances (PFAS), focusing on the interaction between regenerant composition and resin characteristics. The influence of salt type and concentration on PFAS solubility revealed a general decline in perfluorohexane sulfonate (PFHxS) solubility with increased salt concentrations, most strongly with KCl followed by NaCl and NHCl. Mixed solubility results were observed for perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS).
View Article and Find Full Text PDFA mobile interactive cognitive self-assessment scale for screening cognitive impairment due to Alzheimer's disease.
Age Ageing
January 2025
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Background: A mobile cognition scale for community screening in cognitive impairment with rigorous validation is in paucity. We aimed to develop a digital scale that overcame low education for community screening for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and AD.
Methods: A mobile cognitive self-assessment scale (CogSAS) was designed through the Delphi process, which is feasible for the older population with low education.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!